The estimated Net Worth of Justin D. Gover is at least $8.46 Milion dollars as of 26 February 2021. Mr. Gover owns over 440,076 units of GW Pharmaceuticals stock worth over $16,183 and over the last 6 years he sold GWPH stock worth over $579,775. In addition, he makes $7,864,300 as Chief Executive Officer i Executive Director at GW Pharmaceuticals.
Sign up
Mr. Gover GWPH stock SEC Form 4 insiders trading
Justin has made over 14 trades of the GW Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 440,076 units of GWPH stock worth $30,805 on 26 February 2021.
The largest trade he's ever made was exercising 440,076 units of GW Pharmaceuticals stock on 26 February 2021 worth over $30,805. On average, Justin trades about 52,499 units every 33 days since 2018. As of 26 February 2021 he still owns at least 231,185 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Gover stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Justin Gover biography
Justin Gover serves as Chief Executive Officer, Executive Director of the Company. He has 23 years’ experience in the pharmaceutical industry. As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the Company’s operations, as well as leading equity financings, strategy and business development activities. In 2001, he led the Company’s initial public offering on the AIM stock exchange in London, and in 2013 led the Company’s initial public offering in the U.S. on Nasdaq. In total, he has led equity financings which have raised over $1 billion for the Company. In 2015, Mr. Gover relocated to the U.S. to open the Company’s U.S. headquarters in California. Prior to joining the Company, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc (now Amarin Corporation plc), where he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.
What is the salary of Justin Gover?
As the Chief Executive Officer i Executive Director of GW Pharmaceuticals, the total compensation of Justin Gover at GW Pharmaceuticals is $7,864,300. There are no executives at GW Pharmaceuticals getting paid more.
How old is Justin Gover?
Justin Gover is 49, he's been the Chief Executive Officer i Executive Director of GW Pharmaceuticals since 1999. There are 12 older and no younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Justin Gover's mailing address?
Justin's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, Z4, V5G 4W8.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble oraz Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Gover stock trades at GW Pharmaceuticals i Xenon Pharmaceuticals Inc
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America